Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by leveraging the inherent biology of the adaptive immune system to transform disease diagnosis and treatment. Its clinical diagnostic product, clonoSEQ, is an FDA-authorized test for detecting and monitoring minimal residual disease in certain blood cancer patients.